Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/168586
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 1b study from GELTAMO group |
Autor: | Martín, Alejandro; Redondo, Alba; Dlouhy, Iván; Salar, Antonio; González-Barca, Eva; Canales, Miguel; Montes-Moreno, Santiago; Ocio, Enrique M. CSIC ORCID ; López-Guillermo, Armando; Caballero, Maria Dolores | Palabras clave: | Salvage Lenalidomide Diffuse large B-cell lymphoma R-ESHAP Rituximab |
Fecha de publicación: | 2016 | Editor: | John Wiley & Sons | Citación: | British Journal of Haematology 173(2): 245-252 (2016) | Resumen: | Diffuse large B-cell lymphoma (DLBCL) patients failing rituximab-containing therapy have a poor outcome with the current salvage regimens. We conducted a phase 1b trial to determine the maximum tolerated dose (MTD) of lenalidomide in combination with R-ESHAP (rituximab, etoposide, cisplatin, cytarabine, methylprednisolone) (LR-ESHAP) in patients with relapsed or refractory DLBCL. Efficacy data were collected as a secondary objective. Subjects received 3 cycles of lenalidomide at escalating doses (5, 10 or 15 mg) given on days 1-14 of every 21-day cycle, in combination with R-ESHAP. Responding patients received BEAM (carmustine, etoposide, cytarabine, melphalan) followed by autologous stem-cell transplantation. Lenalidomide 10 mg/d was identified as the MTD because, in the 15 mg cohort, one patient experienced dose-limiting toxicity (grade 3 angioedema) and two patients had mobilization failure. A total of 19 patients (3, 12 and 4 in the 5, 10 and 15 mg cohorts, respectively) were evaluable. All toxicities occurring during LR-ESHAP cycles resolved appropriately and no grade 4-5 non-haematological toxicities were observed. The complete remission and overall response rates were 47·4% and 78·9%, respectively. With a median follow-up of 24·6 (17·4-38·2) months, the 2-year progression-free survival and overall survival were 44% and 63%, respectively. In conclusion, the LR-ESHAP regimen is feasible and yields encouraging outcomes. | Descripción: | On behalf of the Grupo Español de Linfomas y Trasplante Autólogo de Médula Ósea (GELTAMO). | URI: | http://hdl.handle.net/10261/168586 | DOI: | 10.1111/bjh.13945 | Identificadores: | doi: 10.1111/bjh.13945 e-issn: 1365-2141 issn: 0007-1048 |
Aparece en las colecciones: | (IBMCC) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
accesoRestringido.pdf | 15,38 kB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
PubMed Central
Citations
9
checked on 10-mar-2024
SCOPUSTM
Citations
23
checked on 16-abr-2024
WEB OF SCIENCETM
Citations
20
checked on 28-feb-2024
Page view(s)
349
checked on 18-abr-2024
Download(s)
116
checked on 18-abr-2024
Google ScholarTM
Check
Altmetric
Altmetric
Artículos relacionados:
NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.